- Home
- GKOS vs ORN Comparison
GKOS vs ORN Comparison
Compare GKOS & ORN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GKOS
- ORN
- Stock Information
- Founded
- GKOS 1998
- ORN 1994
- Country
- GKOS United States
- ORN United States
- Employees
- GKOS N/A
- ORN N/A
- Industry
- GKOS Medical/Dental Instruments
- ORN Military/Government/Technical
- Sector
- GKOS Health Care
- ORN Industrials
- Exchange
- GKOS Nasdaq
- ORN Nasdaq
- Market Cap
- GKOS 5.1B
- ORN N/A
- IPO Year
- GKOS 2015
- ORN 2007
- Fundamental
- Price
- GKOS $97.65
- ORN $6.24
- Analyst Decision
- GKOS Strong Buy
- ORN Strong Buy
- Analyst Count
- GKOS 13
- ORN 3
- Target Price
- GKOS $155.00
- ORN $12.50
- AVG Volume (30 Days)
- GKOS 981.4K
- ORN 322.7K
- Earning Date
- GKOS 04-30-2025
- ORN 04-29-2025
- Dividend Yield
- GKOS N/A
- ORN N/A
- EPS Growth
- GKOS N/A
- ORN N/A
- EPS
- GKOS N/A
- ORN N/A
- Revenue
- GKOS $383,481,000.00
- ORN $796,394,000.00
- Revenue This Year
- GKOS $27.84
- ORN $3.55
- Revenue Next Year
- GKOS $27.99
- ORN $11.66
- P/E Ratio
- GKOS N/A
- ORN N/A
- Revenue Growth
- GKOS 21.85
- ORN 11.89
- 52 Week Low
- GKOS $77.91
- ORN $4.64
- 52 Week High
- GKOS $163.71
- ORN $12.12
- Technical
- Relative Strength Index (RSI)
- GKOS 50.65
- ORN 60.24
- Support Level
- GKOS $87.17
- ORN $5.68
- Resistance Level
- GKOS $94.55
- ORN $5.74
- Average True Range (ATR)
- GKOS 6.20
- ORN 0.35
- MACD
- GKOS 1.57
- ORN 0.13
- Stochastic Oscillator
- GKOS 94.20
- ORN 96.39
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.